Monica Pedroni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/179061/publications.pdf

Version: 2024-02-01

76 papers 2,563 citations

218381 26 h-index 205818 48 g-index

77 all docs

77 docs citations

times ranked

77

3189 citing authors

#	Article	IF	CITATIONS
1	Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework. Diagnosis, 2022, 9, 115-122.	1.2	3
2	Expression of Autophagic and Inflammatory Markers in Normal Mucosa of Individuals with Colorectal Adenomas: A Cross Sectional Study among Italian Outpatients Undergoing Colonoscopy. International Journal of Molecular Sciences, 2022, 23, 5211.	1.8	0
3	Autoimmunity Profiles as Prognostic Indicators in Patients with Colorectal Cancer versus Those with Cancer at Other Sites: A Prospective Study. Cancers, 2021, 13, 3239.	1.7	1
4	Filling the gap: A thorough investigation for the genetic diagnosis of unsolved polyposis patients with monoallelic <i>MUTYH</i> pathogenic variants. Molecular Genetics & amp; Genomic Medicine, 2021, 9, e1831.	0.6	3
5	Risk of colorectal polyps and of malignancies in asymptomatic carriers of mutations in the main DNA mismatch repair genes. Scandinavian Journal of Gastroenterology, 2018, 53, 31-37.	0.6	2
6	Attenuated polyposis of the large bowel: a morphologic and molecular approach. Familial Cancer, 2017, 16, 211-220.	0.9	6
7	Attenuated adenomatous polyposis of the large bowel: Present and future. World Journal of Gastroenterology, 2017, 23, 4135.	1.4	18
8	Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study. Internal and Emergency Medicine, 2016, 11, 41-46.	1.0	4
9	Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. Clinical Epigenetics, 2015, 7, 131.	1.8	45
10	Molecular Features and Methylation Status in Early Onset (â‰ 4 0 Years) Colorectal Cancer: A Population Based, Case-Control Study. Gastroenterology Research and Practice, 2015, 2015, 1-10.	0.7	20
11	Autophagy is upregulated during colorectal carcinogenesis, and in DNA microsatellite stable carcinomas. Oncology Reports, 2015, 34, 3222-3230.	1.2	10
12	Involvement of <i>MBD4</i> inactivation in mismatch repair-deficient tumorigenesis. Oncotarget, 2015, 6, 42892-42904.	0.8	43
13	$\langle i \rangle$ MLH1 $\langle i \rangle$ constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria. Epigenetics, 2014, 9, 1431-1438.	1.3	22
14	Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature. Internal and Emergency Medicine, 2014, 9, 151-160.	1.0	29
15	Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors. Techniques in Coloproctology, 2014, 18, 285-289.	0.8	11
16	An unusual case of familial adenomatous polyposis with very early symptom occurrence. Familial Cancer, 2014, 13, 375-380.	0.9	3
17	MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. European Journal of Human Genetics, 2014, 22, 923-929.	1.4	39
18	Incidence, clinical features and possible etiology of early onset (â‰ 4 0Âyears) colorectal neoplasms. Internal and Emergency Medicine, 2013, 9, 623-31.	1.0	6

#	Article	IF	CITATIONS
19	Incidence trend of malignant polyps through the data of a specialized colorectal cancer registry: clinical features and effect of screening. Scandinavian Journal of Gastroenterology, 2013, 48, 1294-1301.	0.6	13
20	Duodenal carcinoma in a 37-year-old man with Cowden/Bannayan syndrome. Digestive and Liver Disease, 2013, 45, 75-78.	0.4	9
21	Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. Techniques in Coloproctology, 2013, 17, 79-87.	0.8	12
22	A case of pneumatosis cystoides intestinalis mimicking familial adenomatous polyposis. Familial Cancer, 2013, 12, 573-576.	0.9	3
23	Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study. Acta Oncol \tilde{A}^3 gica, 2013, 52, 1682-1690.	0.8	13
24	Th Inducing POZ-Kruppel Factor (ThPOK) Is a Key Regulator of the Immune Response since the Early Steps of Colorectal Carcinogenesis. PLoS ONE, 2013, 8, e54488.	1.1	8
25	MSH3 Protein Expression and Nodal Status in MLH1-Deficient Colorectal Cancers. Clinical Cancer Research, 2012, 18, 3142-3153.	3.2	21
26	Clinical and molecular characterization of colorectal cancer in young Moroccan patients. Turkish Journal of Gastroenterology, 2012, 23, 686-690.	0.4	5
27	Lanthanide doped upconverting colloidal CaF2 nanoparticles prepared by a single-step hydrothermal method: toward efficient materials with near infrared-to-near infrared upconversion emission. Nanoscale, 2011, 3, 1456.	2.8	76
28	Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome. Cancer, 2011, 117, 4325-4335.	2.0	12
29	Analysis of mismatch repair gene mutations in Turkish HNPCC patients. Familial Cancer, 2010, 9, 365-376.	0.9	10
30	Prognostic Relevance of MLH1 and MSH2 Mutations in Hereditary Non-Polyposis Colorectal Cancer Patients. Tumori, 2009, 95, 731-738.	0.6	8
31	Relative role of <i>APC </i> and <i>MUTYH </i> mutations in the pathogenesis of familial adenomatous polyposis. Scandinavian Journal of Gastroenterology, 2009, 44, 1092-1100.	0.6	17
32	Myeloperoxidase-Positive Cell Infiltration in Colorectal Carcinogenesis as Indicator of Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2291-2297.	1.1	83
33	Genotype-phenotype correlations in individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 746-753.	0.6	10
34	O6-methylguanine-DNA methyltransferase promoter hypermethylation in colorectal carcinogenesis. Oncology Reports, 2007, 17, 1421.	1.2	5
35	BRAF Mutations in Multiple Sebaceous Hyperplasias of Patients Belonging to MYH-Associated Polyposis Pedigrees. Journal of Investigative Dermatology, 2007, 127, 1387-1391.	0.3	17
36	Frequency of constitutional <i>MSH6 </i> mutations in a consecutive series of families with clinical suspicion of HNPCC. Clinical Genetics, 2007, 72, 230-237.	1.0	16

#	Article	IF	CITATIONS
37	Epidemiology of colorectal cancer: the 21-year experience of a specialised registry. Internal and Emergency Medicine, 2007, 2, 269-279.	1.0	27
38	Immunohistochemical Expression of MYH Protein Can Be Used to Identify Patients With MYH-Associated Polyposis. Gastroenterology, 2006, 131, 439-444.	0.6	24
39	Value of MLH1 and MSH2 Mutations in the Appearance of Muir–Torre Syndrome Phenotype in HNPCC Patients Presenting Sebaceous Gland Tumors or Keratoacanthomas. Journal of Investigative Dermatology, 2006, 126, 2302-2307.	0.3	93
40	Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathology Research and Practice, 2006, 202, 663-670.	1.0	43
41	Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. Clinical Genetics, 2005, 68, 442-447.	1.0	76
42	Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families. British Journal of Dermatology, 2005, 152, 1335-1338.	1.4	31
43	Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas. Cancer, 2005, 103, 1018-1025.	2.0	136
44	Incidence and survival of patients with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study. International Journal of Colorectal Disease, 2005, 20, 147-154.	1.0	20
45	Investigation of APC Mutations in a Turkish Familial Adenomatous Polyposis Family by Heterodublex Analysis. Diseases of the Colon and Rectum, 2005, 48, 567-571.	0.7	3
46	Molecular Genetic Alterations and Clinical Features in Early-Onset Colorectal Carcinomas and Their Role for the Recognition of Hereditary Cancer Syndromes. American Journal of Gastroenterology, 2005, 100, 2280-2287.	0.2	66
47	Microsatellite Instability and Colorectal Cancer Prognosis. Clinical Cancer Research, 2005, 11, 8332-8340.	3.2	339
48	Aetiology of colorectal cancer and relevance of monogenic inheritance. Gut, 2004, 53, 115-122.	6.1	33
49	Trend of incidence, subsite distribution and staging of colorectal neoplasms in the 15-year experience of a specialised cancer registry. Annals of Oncology, 2004, 15, 940-946.	0.6	56
50	A founder MLH1 mutation in families from the districts of Modena and Reggio-Emilia in northern Italy with hereditary non-polyposis colorectal cancer associated with protein elongation and instability. Journal of Medical Genetics, 2004, 41, 34e-34.	1.5	22
51	Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. British Journal of Cancer, 2004, 90, 882-887.	2.9	57
52	Relationship between MUC5AC and altered expression of MLH1 protein in mucinous and non-mucinous colorectal carcinomas. Pathology Research and Practice, 2004, 200, 371-377.	1.0	26
53	Molecular Screening for Hereditary Nonpolyposis Colorectal Cancer: A Prospective, Population-Based Study. Journal of Clinical Oncology, 2001, 19, 3944-3950.	0.8	101
54	Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes and Cancer, 2001, 31, 357-361.	1.5	53

#	Article	lF	Citations
55	Mutations of the 'minor' mismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. Familial Cancer, 2001, 1, 95-101.	0.9	24
56	Clinical and biologic heterogeneity of hereditary nonpolyposis colorectal cancer. International Journal of Cancer, 2001, 95, 323-328.	2.3	19
57	Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts., 2000, 27, 424-429.		19
58	Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Proliferation, 2000, 33, 1-18.	2.4	105
59	Problems in the identification of hereditary nonpolyposis colorectal cancer in two families with late development of full-blown clinical spectrum. American Journal of Gastroenterology, 2000, 95, 2110-2115.	0.2	3
60	Problems in the identification of hereditary nonpolyposis colorectal cancer in two families with late development of full-blown clinical spectrum. American Journal of Gastroenterology, 2000, 95, 2110-2115.	0.2	2
61	Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts., 2000, 27, 424.		1
62	Microsatellite instability in multiple colorectal tumors. , 1999, 81, 1-5.		72
63	Evaluation of the replication error phenotype in relation to molecular and clinicopathological features in hereditary and early onset colorectal cancer. European Journal of Cancer, 1999, 35, 289-295.	1.3	13
64	Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal cancer susceptibility. Human Genetics, 1998, 102, 15-20.	1.8	56
65	Small bowel carcinoma in hereditary nonpolyposis colorectal cancer. American Journal of Gastroenterology, 1998, 93, 2219-2222.	0.2	15
66	Aberrant crypt foci in patients with colorectal cancer. British Journal of Cancer, 1998, 77, 2343-2348.	2.9	53
67	Histology of aberrant crypt foci in the human colon. Histopathology, 1997, 30, 328-334.	1.6	73
68	K-ras andp53 mutations in hereditary non-polyposis colorectal cancers. International Journal of Cancer, 1997, 74, 94-96.	2.3	80
69	Clinical features, frequency and prognosis of Dukes' A colorectal carcinoma: A population-based investigation. European Journal of Cancer, 1996, 32, 1957-1962.	1.3	15
70	Frequency and clinical features of multiple tumors of the large bowel in the general population and in patients with hereditary colorectal carcinoma., 1996, 77, 2013-2021.		61
71	Biologic Characterization of Hereditary Non-Polyposis Colorectal Cancer: <i>Nuclear Ploidy, AgNOR Count, Microvessel Distribution, Oncogene Expression, and Grade-Related Parameters</i> Journal of Clinical Pathology, 1995, 103, 265-270.	0.4	28
72	Argyrophilic nucleolar organizer regions and bromodeoxyuridine and [H]-thymidine labelling indices in colorectal cancer. Cell Proliferation, 1995, 28, 471-480.	2.4	1

#	Article	IF	CITATION
73	Risk of cancer revealed by follow-up of families with hereditary non-polyposis colorectal cancer: Reply to Dr. Eluf-Neto. International Journal of Cancer, 1995, 61, 744-744.	2.3	0
74	Tumour spectrum in hereditary non-polyposis colorectal cancer (HNPCC) and in families with "suspected hnpcc― A population-based study in northern Italy. International Journal of Cancer, 1993, 54, 371-377.	2.3	73
75	Risk of cancer revealed by follow-up of families with hereditary non-polyposis colorectal cancer: A population-based study. International Journal of Cancer, 1993, 55, 202-207.	2.3	22
76	Cell kinetics evaluation of colorectal tumors afterin vivo administration of bromodeoxyuridine. International Journal of Cancer, 1992, 52, 856-861.	2.3	19